Elections › Corporate Influence › NOVARTIS

🏛️ NOVARTIS

CORPORATE LOBBYING & ELECTION INFLUENCE PROFILE

$16.9M
Lobbying Spend
$0
Campaign Spending
74
Lobbyists
0
Races Influenced
57
LDA Filings
Lobbying Issue Areas
🏥 Healthcare & Pharma🏭 Trade & Manufacturing🛡️ Defense & Security🤖 Tech & AI
Filing Quarters
first_quarterfourth_quartersecond_quarterthird_quarter
Specific Lobbying Issues
Issues related to the pharmaceutical industry.
Issues related to the pharmaceutical industry.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Cons
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - M
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues
Where the Money Is Going
Race Campaign $ Candidate(s)
No race-level spending data linked yet.
Source: Senate LDA lobbying disclosures + FEC campaign finance data + USAspending.gov via Hammerhead Intelligence
Lobbying $ = annual reported federal lobbying expenditures (company-wide). Campaign $ = IE spending directed at candidates in specific races. Govt Contracts $ = federal awards from USAspending.gov.
Last updated: 2026-04-25